What Has Been The Evolution of the Actemra Tocilizumab Market in Recent Years?
The actemra tocilizumab market has seen considerable growth due to a variety of factors.
• The market value for Actemra (tocilizumab) has seen a significant increase in recent years. It's projected to escalate from $5,160 million in 2024 to $5,710 million in 2025, manifesting a compound annual growth rate (CAGR) of 10.7%.
This growth during the historical timeframe could be credited to the rising frequency of autoimmune disorders, increased use of biologic treatments, heightened awareness about persistent inflammatory conditions, robust regulatory endorsements in essential markets, and improved healthcare facilities in developed zones.
What Is the Forecasted Market Size and Growth Rate for The Actemra Tocilizumab Template Market?
The actemra tocilizumab market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for Actemra (tocilizumab) is anticipated to drastically expand in the forthcoming years, reaching a figure of $8,480 million in 2029, with a compound annual growth rate (CAGR) of 10.4%.
This substantial growth during the projected period is due to the enhancement of therapeutic applications like COVID-19 cytokine release syndrome, the rising need for personalized medication, the development and acceptance of biosimilars, increased investment in healthcare in emerging markets, and the growth of biologic therapies knowledge in developing areas. Major trends anticipated in this forecast period include the increased acceptance of subcutaneous versions, a mounting focus on biosimilar development for cost-cutting, advancements in biotechnological strategies for better drug delivery systems, ongoing clinical examinations for new therapeutic usage, and strategic collaborations and investments by pharmaceutical firms.
What Factors Are Driving Growth In The Actemra Tocilizumab Market?
The growth of the Actemra (tocilizumab) market is anticipated to be propelled by the increasing incidence of rheumatoid arthritis. Rheumatoid arthritis, a chronic autoimmune disease that results in joint inflammation, damage and impairment of life quality, affects millions across the globe. Influenced by factors like smoking, obesity, environmental exposures, and hormonal aspects, this disease sees Actemra (tocilizumab) as one of its viable treatments, as it reduces inflammation and prevents joint damage by blocking the interleukin-6 (IL-6) receptor, especially in patients who aren't responding to alternate treatments. As per data released by the National Institute for Health and Care Research (NIHR), a UK government agency, in April 2024, around 700,000 individuals in the UK were diagnosed with rheumatoid arthritis. Also, according to a report issued by the Australian Institute of Health and Welfare, a national agency in Australia, in June 2024, approximately 514,000 people in Australia (representing 2.0% of the population) had rheumatoid arthritis in 2022. In 2023, this disorder constituted 2.0% of the overall disease burden and 16% of the musculoskeletal disease burden. Rheumatoid arthritis was also associated with 1,322 fatalities in 2022, translating to 5.1 deaths per 100,000 individuals and corresponding to 0.7% of all deaths. Therefore, the escalating prevalence of rheumatoid arthritis is giving a boost to the Actemra (tocilizumab) market.
What Are The Main Segments Of The Global Actemra Tocilizumab Market?
The actemra (tocilizumab) market covered in this report is segmented –
1) By Product Type: Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
2) By Dosage: Injection, Solution, Concentrate
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By Application: Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), Rheumatoid Arthritis (RA)
Pre-Book The Actemra Tocilizumab Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Actemra Tocilizumab Market?
The actemra (tocilizumab) market is trending towards the implementation of innovative enhancements, like the tocilizumab biosimilar, to secure an industry lead. Tocilizumab biosimilars, approved for autoimmune diseases and COVID-19 treatment, provide an alternative to the pioneering drug, Actemra. For instance, Fresenius Kabi, a healthcare enterprise based in Germany, introduced Tyenne in November 2023. This was the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne has received approval for treating a variety of inflammatory and immune conditions such as rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokine release syndrome (CRS), and COVID-19.
Who Are the Key Players In The Actemra Tocilizumab Market?
Major companies operating in the actemra (tocilizumab) market include:
• Roche Holding AG
• Fresenius Kabi
What Is The Most Dominant Region In The Actemra Tocilizumab Market?
North America was the largest region in the actemra (Tocilizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actemra (tocilizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
